A5090619468- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- RNA Interference and Gene Delivery
- Genomics and Rare Diseases
- Pharmaceutical industry and healthcare
- Connexins and lens biology
- Parkinson's Disease and Spinal Disorders
- Advanced Causal Inference Techniques
- Neurogenetic and Muscular Disorders Research
- Osteoarthritis Treatment and Mechanisms
- Biochemical effects in animals
- Inflammatory mediators and NSAID effects
- Immunotherapy and Immune Responses
- Glaucoma and retinal disorders
- ATP Synthase and ATPases Research
- Genetic Neurodegenerative Diseases
- Immune Response and Inflammation
- Cardiac, Anesthesia and Surgical Outcomes
- Dementia and Cognitive Impairment Research
- Cell death mechanisms and regulation
- Genetic Syndromes and Imprinting
- Gastric Cancer Management and Outcomes
Eli Lilly (United States)
2015-2022
National Patient Safety Foundation
2022
Washington University in St. Louis
2005-2006
Mallinckrodt (United States)
2005
To image apoptosis in vivo with a small, membrane-permeant probe, TcapQ647 was synthesized comprising Tat-peptide-based permeation peptide sequence, an effector caspase recognition DEVD, and flanking optically activatable pair far-red quencher, QSY 21, fluorophore, Alexa Fluor 647. Under baseline conditions, high quenching efficiencies were observed resulting low background fluorescence. Upon exposure to executioner caspases, specifically cleaved, thereby releasing the fluorophore from...
Apoptosis is a key pathogenic mechanism in sepsis that induces extensive death of lymphocytes and dendritic cells, thereby contributing to the immunosuppression characterizes septic disorder. Numerous animal studies indicate prevention apoptosis improves survival may represent potential therapy for this highly lethal Recently, novel cell-penetrating peptide constructs such as HIV-1 TAT basic domain related peptides have been developed deliver bioactive cargoes into cells. In present study,...
Abstract Introduction It has become increasingly important to include patient preference information in decision-making processes for drug development. As neuromuscular disorders represent multisystem, debilitating, and progressive rare diseases with few treatment options, this study aimed explore unmet health care needs preferences two disorders, myotonic dystrophy type 1 (DM1) mitochondrial myopathies (MM) inform early stages of Methods Fifteen semi-structured interviews five focus group...
We aimed to assess the feasibility of developing a discrete-choice experiment survey elicit preferences for treatment delay cognitive decline among people with clinical syndrome consistent early Alzheimer's disease, including development self-reported screening criteria recruit sample. Using input from qualitative interviews, we developed containing multifaceted beneficial attribute related slowing respondents concerns. In two rounds in-person pretest tested and revised text questions,...
A correction to this paper has been published: https://doi.org/10.1007/s40271-021-00523-1